What is SS-31?
SS-31, also known as elamipretide, is a small aromatic-cationic tetrapeptide that selectively concentrates in the inner mitochondrial membrane. It is designed to bind cardiolipin, a phospholipid essential for electron transport chain organization and mitochondrial cristae structure.
How does SS-31 work?
SS-31 stabilizes cardiolipin interactions with respiratory-chain complexes, helping maintain efficient electron transport and reduce pathologic reactive oxygen species production. By improving mitochondrial coupling under stress, it may support ATP production in tissues with high energy demand such as skeletal muscle, heart, and retina.
Primary Documented Uses
- Clinical-trial research in primary mitochondrial diseases
- Experimental cardioprotection and skeletal-muscle energetics
- Research into oxidative stress and mitochondrial membrane stability
- Potential rare-disease therapy development
Research Summary
Clinical trials have evaluated elamipretide in primary mitochondrial myopathy, Barth syndrome, heart failure, and geographic atrophy. Results have been mixed, with some studies showing improvements in functional or patient-reported endpoints while others did not meet primary endpoints, keeping the compound investigational.
Legal and Regulatory Status
Elamipretide is investigational and not FDA-approved for general clinical use. Access should occur only through clinical trials, expanded access programs, or authorized research settings.
Frequently Asked Questions
What is SS-31?
SS-31 is A mitochondria-targeted tetrapeptide designed to stabilize cardiolipin and improve mitochondrial energy production under stress.
How does SS-31 work?
SS-31 stabilizes cardiolipin interactions with respiratory-chain complexes, helping maintain efficient electron transport and reduce pathologic reactive oxygen species production. By improving mitochondrial coupling under stress, it may support ATP production in tissues with high energy demand such as skeletal muscle, heart, and retina.
What does research say about SS-31?
Clinical trials have evaluated elamipretide in primary mitochondrial myopathy, Barth syndrome, heart failure, and geographic atrophy. Results have been mixed, with some studies showing improvements in functional or patient-reported endpoints while others did not meet primary endpoints, keeping the compound investigational.
Is SS-31 FDA-approved or legally available?
Elamipretide is investigational and not FDA-approved for general clinical use. Access should occur only through clinical trials, expanded access programs, or authorized research settings.